Can a Three-Drug combo quiet lupus kidney flares?

NCT ID NCT07760480

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests whether adding voclosporin to standard lupus nephritis treatment (mycophenolate mofetil and prednisolone) reduces kidney inflammation faster and more completely than standard treatment alone. Adults with active lupus nephritis will be randomly assigned to either triple or dual therapy, and will undergo kidney biopsies before and after 3 months of treatment to see how immune cells in the kidney respond. The study also looks for blood or urine markers that could monitor disease without repeated biopsies, and follows participants for up to 2 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
voclosporin added to standard treatment with mycophenolate mofetil and prednisolone
What this could lead to
If adding voclosporin works, it could lead to faster and more complete remission of kidney inflammation in lupus nephritis, potentially preserving kidney function and reducing long-term damage.
What could go wrong
This is a relatively small, early-phase trial, so results may not apply broadly. Adding voclosporin may increase side effects without improving outcomes, and the study's focus on early tissue changes may not predict long-term benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Amsterdam University Medical Center

    RECRUITING

    Amsterdam, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.